Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: A Gynecologic Oncology Group study

Authors

Jennifer M. Rubatt, Magee-Womens Hospital, Pittsburgh, PA
Kathleen M. Darcy, Roswell Park Cancer Institute, Buffalo, NY
Chunqiao Tian, Roswell Park Cancer Institute, Buffalo, NY
Franco Muggia, New York University
Rajiv Dhir, University of Pittsburgh
Deborah K. Armstrong, Johns Hopkins University
Michael A. Bookman, Arizona Cancer Center, Tucson, AZ
Laura J. Niedernhofer, University of Pittsburgh
Julie A. DeLoia, George Washington University
Michael Birrer, Massachusetts General Hospital, Boston, MA
Thomas C. Krivak, University of Pittsburgh

Document Type

Journal Article

Publication Date

5-2012

Journal

Gynecologic Oncology

Volume

Volume 125, Issue 2

Inclusive Pages

421-426

Keywords

DNA-Binding Proteins--biosynthesis; Endonucleases--biosynthesis; Neoplasms; Glandular and Epithelial--enzymology; Ovarian Neoplasms--enzymology; Tumor Markers; Biological--biosynthesis

Comments

This is an open access PubMed Central article. Click on link for full-text access.

APA Citation

Rubatt, J. M., Darcy, K. M., Tian, C., Muggia, F., Dhir, R., Armstrong, D. K., Bookman, M.A., Niedernhofer, L.J., Deloia, J., Birrer, M., Krivak, T. C. (2012). Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: A gynecologic oncology group study. Gynecologic Oncology, 125(2), 421-426.

Peer Reviewed

1

Open Access

1